Description
Recombinant Cynomolgus PD-L1/B7-H1/CD274 Protein (Fc Tag) | PKSQ050046 | Gentaur US, UK & Europe Disrtribition
Synonyms: B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1
Active Protein: N/A
Activity: Recombinant Cynomolgus PD-L1 is produced by our Mammalian expression system and the target gene encoding Phe19-Thr239 is expressed with a Fc tag at the C-terminus.
Protein Construction: Recombinant Cynomolgus PD-L1 is produced by our Mammalian expression system and the target gene encoding Phe19-Thr239 is expressed with a Fc tag at the C-terminus.
Fusion Tag: C-Fc
Species: Cynomolgus
Expressed Host: Human Cells
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 95 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per μg as determined by the LAL method.
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 52.4 kDa
Formulation: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Reconstitution: Please refer to the printed manual for detailed information.
Background: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.
Research Area: N/A
